In Silico Drug Repurposing Studies for the Discovery of Novel Salicyl-AMP Ligase (MbtA)Inhibitors
Abstract
:1. Introduction
2. Materials and Methods
2.1. System Specifications and Software Employed
2.2. Ligand Preparation
2.3. Protein Preparation
2.4. Identification of Binding Site and Receptor Grid Generation
2.5. Docking-Based Virtual Screening Studies
2.6. Molecular Dynamics Studies
2.7. Principal Component Analysis (PCA)
3. Results
3.1. Molecular Docking Studies on MbtA
3.1.1. Validation of Docking Procedure
3.1.2. Virtual Screening of FDA-Reported Library through Molecular Docking
- a_617: Cobicistat–MbtA complex (Figure S1a)
- 2.
- a_391: Saquinavir–MbtA complex (Figure S1b)
- 3.
- a_821: Carfilzomib–MbtA complex (Figure S1c)
- 4.
- a_827: Candesartan–MbtA complex (Figure S1d)
- 5.
- a_85: Ritonavir–MbtA complex (Figure S1e)
- 6.
- a_472: Lopinavir–MbtA complex (Figure S1f)
- 7.
- a_1276: Indinavir–MbtA complex (Figure S1g)
- 8.
- a_1338: Venetoclax–MbtA complex (Figure S1h)
- 9.
- a_797: Zafirlukast (Accolate)–MbtA complex (Figure S1i)
- 10.
- a_1388: Neratinib–MbtA complex (Figure S1j)
3.2. Molecular Dynamics Simulation Study
4. Principal Component Analysis (PCA)
5. Discussion
6. Conclusions
7. Future Scope
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Borah, P.; Deb, P.K.; Venugopala, K.N.; Al-Shar’i, N.A.; Singh, V.; Deka, S.; Srivastava, A.; Tiwari, V.; Mailavaram, R.P. Tuberculosis: An Update on Pathophysiology, Molecular Mechanisms of Drug Resistance, Newer Anti-TB Drugs, Treatment Regimens and Host-Directed Therapies. Curr. Top. Med. Chem. 2021, 21, 547–570. [Google Scholar] [CrossRef] [PubMed]
- World Health Organization. Tuberculosis: Key Facts. Available online: https://www.who.int/news-room/fact-sheets/detail/tuberculosis (accessed on 18 September 2023).
- Peddireddy, V.; Doddam, S.N.; Ahmed, N. Mycobacterial Dormancy Systems and Host Responses in Tuberculosis. Front. Immunol. 2017, 8, 84. [Google Scholar] [CrossRef] [PubMed]
- Shyam, M.; Shilkar, D.; Verma, H.; Dev, A.; Sinha, B.N.; Brucoli, F.; Bhakta, S.; Jayaprakash, V. The Mycobactin Biosynthesis Pathway: A Prospective Therapeutic Target in the Battle against Tuberculosis. J. Med. Chem. 2020, 64, 71–100. [Google Scholar] [CrossRef]
- Prasad, R.; Singh, A.; Balasubramanian, V.; Gupta, N. Extensively Drug-Resistant Tuberculosis in India: Current Evidence on Diagnosis & Management. Indian J. Med. Res. 2017, 145, 271. [Google Scholar]
- Velayati, A.A.; Farnia, P.; Hoffner, S. Drug-Resistant Mycobacterium Tuberculosis: Epidemiology and Role of Morphological Alterations. J. Glob. Antimicrob. Resist. 2018, 12, 192–196. [Google Scholar] [CrossRef] [PubMed]
- Rakshit, G.; Jayaprakash, V. Tuberculosis and HIV Responses Threatened by NCOVID-19: A Situation Prompting an in Silico Investigation of Reported MbtA Inhibitors for Combined Inhibition of SARS-CoV-2 and HIV-TB Co-Infection. Struct. Chem. 2023, 34, 655–679. [Google Scholar] [CrossRef]
- Sibi, D.; Sethi Das, C.; Jibin, V.G.; Silvanose, C.D. Emerging Antibiotic Resistance in Post-COVID-19 Co-Infections. J. Clin. Med. Case Rep. 2023, 8, 8. [Google Scholar]
- Pawlowski, A.; Jansson, M.; Sköld, M.; Rottenberg, M.E.; Källenius, G. Tuberculosis and HIV Co-Infection. PLoS Pathog. 2012, 8, e1002464. [Google Scholar] [CrossRef]
- Shyam, M.; Shilkar, D.; Rakshit, G.; Jayaprakash, V. Approaches for Targeting the Mycobactin Biosynthesis Pathway for Novel Anti-Tubercular Drug Discovery: Where We Stand. Expert. Opin. Drug Discov. 2022, 17, 699–715. [Google Scholar] [CrossRef]
- Miethke, M.; Marahiel, M.A. Siderophore-Based Iron Acquisition and Pathogen Control. Microbiol. Mol. Biol. Rev. 2007, 71, 413–451. [Google Scholar] [CrossRef]
- Quadri, L.E.N. Iron Uptake in Mycobacteria. In The Mycobacterial Cell Envelope; Wiley & Sons: Hoboken, NJ, USA, 2008; pp. 167–184. [Google Scholar]
- Hammer, N.D.; Skaar, E.P. Molecular Mechanisms of Staphylococcus Aureus Iron Acquisition. Annu. Rev. Microbiol. 2011, 65, 129–147. [Google Scholar] [CrossRef]
- Barclay, R.; Ewing, D.F.; Ratledge, C. Isolation, Identification, and Structural Analysis of the Mycobactins of Mycobacterium Avium, Mycobacterium Intracellulare, Mycobacterium Scrofulaceum, and Mycobacterium Paratuberculosis. J. Bacteriol. 1985, 164, 896–903. [Google Scholar] [CrossRef] [PubMed]
- Hall, R.M.; Ratledge, C. A Simple Method for the Production of Mycobactin, the Lipid-Soluble Siderophore, from Mycobacteria. FEMS Microbiol. Lett. 1982, 15, 133–136. [Google Scholar] [CrossRef]
- De Voss, J.J.; Rutter, K.; Schroeder, B.G.; Su, H.; Zhu, Y.; Barry, C.E., III. The Salicylate-Derived Mycobactin Siderophores of Mycobacterium Tuberculosis Are Essential for Growth in Macrophages. Proc. Natl. Acad. Sci. USA 2000, 97, 1252–1257. [Google Scholar] [CrossRef] [PubMed]
- Barry, S.M.; Challis, G.L. Recent Advances in Siderophore Biosynthesis. Curr. Opin. Chem. Biol. 2009, 13, 205–215. [Google Scholar] [CrossRef] [PubMed]
- Snow, G. Mycobactins: Iron-Chelating Growth Factors from Mycobacteria. Bacteriol. Rev. 1970, 34, 99–125. [Google Scholar] [CrossRef]
- Sritharan, M. Iron Homeostasis in Mycobacterium Tuberculosis: Mechanistic Insights into Siderophore-Mediated Iron Uptake. J. Bacteriol. 2016, 198, 2399–2409. [Google Scholar] [CrossRef] [PubMed]
- Wells, R.M.; Jones, C.M.; Xi, Z.; Speer, A.; Danilchanka, O.; Doornbos, K.S.; Sun, P.; Wu, F.; Tian, C.; Niederweis, M. Discovery of a Siderophore Export System Essential for Virulence of Mycobacterium Tuberculosis. PLoS Pathog. 2013, 9, e1003120. [Google Scholar] [CrossRef]
- Choudhury, M.; Koduru, T.N.; Kumar, N.; Salimi, S.; Desai, K.; Prabhu, N.P.; Sritharan, M. Iron Uptake and Transport by the Carboxymycobactin-Mycobactin Siderophore Machinery of Mycobacterium Tuberculosis Is Dependent on the Iron-Regulated Protein HupB. BioMetals 2021, 34, 511–528. [Google Scholar] [CrossRef]
- Rodriguez, G.M.; Smith, I. Identification of an ABC Transporter Required for Iron Acquisition and Virulence in Mycobacterium Tuberculosis. J. Bacteriol. 2006, 188, 424–430. [Google Scholar] [CrossRef]
- Ryndak, M.B.; Wang, S.; Smith, I.; Rodriguez, G.M. The Mycobacterium Tuberculosis High-Affinity Iron Importer, IrtA, Contains an FAD-Binding Domain. J. Bacteriol. 2010, 192, 861–869. [Google Scholar] [CrossRef] [PubMed]
- Gupta, V.; Gupta, R.K.; Khare, G.; Salunke, D.M.; Tyagi, A.K. Crystal Structure of Bfr A from Mycobacterium Tuberculosis: Incorporation of Selenomethionine Results in Cleavage and Demetallation of Haem. PLoS ONE 2009, 4, e8028. [Google Scholar] [CrossRef] [PubMed]
- Yao, H.; Wang, Y.; Lovell, S.; Kumar, R.; Ruvinsky, A.M.; Battaile, K.P.; Vakser, I.A.; Rivera, M. The Structure of the BfrB–Bfd Complex Reveals Protein–Protein Interactions Enabling Iron Release from Bacterioferritin. J. Am. Chem. Soc. 2012, 134, 13470–13481. [Google Scholar] [CrossRef] [PubMed]
- Siegrist, M.S.; Unnikrishnan, M.; McConnell, M.J.; Borowsky, M.; Cheng, T.-Y.; Siddiqi, N.; Fortune, S.M.; Moody, D.B.; Rubin, E.J. Mycobacterial Esx-3 Is Required for Mycobactin-Mediated Iron Acquisition. Proc. Natl. Acad. Sci. USA 2009, 106, 18792–18797. [Google Scholar] [CrossRef] [PubMed]
- Serafini, A.; Pisu, D.; Palù, G.; Rodriguez, G.M.; Manganelli, R. The ESX-3 Secretion System Is Necessary for Iron and Zinc Homeostasis in Mycobacterium Tuberculosis. PLoS ONE 2013, 8, e78351. [Google Scholar] [CrossRef] [PubMed]
- Jones, C.M.; Wells, R.M.; Madduri, A.V.R.; Renfrow, M.B.; Ratledge, C.; Moody, D.B.; Niederweis, M. Self-Poisoning of Mycobacterium Tuberculosis by Interrupting Siderophore Recycling. Proc. Natl. Acad. Sci. USA 2014, 111, 1945–1950. [Google Scholar] [CrossRef] [PubMed]
- Shyam, M.; Verma, H.; Bhattacharje, G.; Mukherjee, P.; Singh, S.; Kamilya, S.; Jalani, P.; Das, S.; Dasgupta, A.; Mondal, A. Mycobactin Analogues with Excellent Pharmacokinetic Profile Demonstrate Potent Antitubercular Specific Activity and Exceptional Efflux Pump Inhibition. J. Med. Chem. 2022, 65, 234–256. [Google Scholar] [CrossRef] [PubMed]
- Stirrett, K.L.; Ferreras, J.A.; Jayaprakash, V.; Sinha, B.N.; Ren, T.; Quadri, L.E.N. Small Molecules with Structural Similarities to Siderophores as Novel Antimicrobials against Mycobacterium Tuberculosis and Yersinia Pestis. Bioorg. Med. Chem. Lett. 2008, 18, 2662–2668. [Google Scholar] [CrossRef]
- Ferreras, J.A.; Gupta, A.; Amin, N.D.; Basu, A.; Sinha, B.N.; Worgall, S.; Jayaprakash, V.; Quadri, L.E.N. Chemical Scaffolds with Structural Similarities to Siderophores of Nonribosomal Peptide-Polyketide Origin as Novel Antimicrobials against Mycobacterium Tuberculosis and Yersinia Pestis. Bioorg. Med. Chem. Lett. 2011, 21, 6533–6537. [Google Scholar] [CrossRef]
- Sterling, T.; Irwin, J.J. ZINC 15–Ligand Discovery for Everyone. J. Chem. Inf. Model. 2015, 55, 2324–2337. [Google Scholar] [CrossRef]
- Irwin, J.J.; Tang, K.G.; Young, J.; Dandarchuluun, C.; Wong, B.R.; Khurelbaatar, M.; Moroz, Y.S.; Mayfield, J.; Sayle, R.A. ZINC20—A Free Ultralarge-Scale Chemical Database for Ligand Discovery. J. Chem. Inf. Model. 2020, 60, 6065–6073. [Google Scholar] [CrossRef]
- Varadi, M.; Anyango, S.; Deshpande, M.; Nair, S.; Natassia, C.; Yordanova, G.; Yuan, D.; Stroe, O.; Wood, G.; Laydon, A.; et al. AlphaFold Protein Structure Database: Massively Expanding the Structural Coverage of Protein-Sequence Space with High-Accuracy Models. Nucleic Acids Res. 2022, 50, D439–D444. [Google Scholar] [CrossRef]
- Berman, H.M.; Westbrook, J.; Feng, Z.; Gilliland, G.; Bhat, T.N.; Weissig, H.; Shindyalov, I.N.; Bourne, P.E. The Protein Data Bank. Nucleic Acids Res. 2000, 28, 235–242. [Google Scholar] [CrossRef] [PubMed]
- Morris, G.M.; Goodsell, D.S.; Huey, R.; Hart, W.E.; Halliday, S.; Belew, R.; Olson, A.J. AutoDock. In Automated Docking of Flexible Ligands to Receptor-User Guide; 2001; Available online: https://citeseerx.ist.psu.edu/document?repid=rep1&type=pdf&doi=e992478dcbeaec5be4850f4b9f46218306e36a4e (accessed on 18 September 2023).
- Rizvi, S.M.D.; Shakil, S.; Haneef, M. A Simple Click by Click Protocol to Perform Docking: Autodock 4.2 Made Easy for Non-Bioinformaticians. EXCLI J. 2013, 12, 830–857. [Google Scholar]
- Van Der Spoel, D.; Lindahl, E.; Hess, B.; Groenhof, G.; Mark, A.E.; Berendsen, H.J.C. GROMACS: Fast, Flexible, and Free. J. Comput. Chem. 2005, 26, 1701–1718. [Google Scholar] [CrossRef] [PubMed]
- DeLano, W.L. Pymol: An Open-Source Molecular Graphics Tool. CCP4 Newsl. Protein Crystallogr. 2002, 40, 82–92. [Google Scholar]
- Laskowski, R.A.; Swindells, M.B. LigPlot+: Multiple Ligand–Protein Interaction Diagrams for Drug Discovery. J. Chem. Inf. Model. 2011, 51, 2778–2786. [Google Scholar] [CrossRef]
- Irwin, J.J.; Shoichet, B.K. ZINC− a Free Database of Commercially Available Compounds for Virtual Screening. J. Chem. Inf. Model. 2005, 45, 177–182. [Google Scholar] [CrossRef]
- O’Boyle, N.M.; Banck, M.; James, C.A.; Morley, C.; Vandermeersch, T.; Hutchison, G.R. Open Babel: An Open Chemical Toolbox. J. Cheminform. 2011, 3, 1–14. [Google Scholar] [CrossRef]
- May, J.J.; Kessler, N.; Marahiel, M.A.; Stubbs, M.T. Crystal Structure of DhbE, an Archetype for Aryl Acid Activating Domains of Modular Nonribosomal Peptide Synthetases. Proc. Natl. Acad. Sci. USA 2002, 99, 12120–12125. [Google Scholar] [CrossRef]
- Vergnolle, O.; Xu, H.; Tufariello, J.M.; Favrot, L.; Malek, A.A.; Jacobs, W.R.; Blanchard, J.S. Post-Translational Acetylation of MbtA Modulates Mycobacterial Siderophore Biosynthesis. J. Biol. Chem. 2016, 291, 22315–22326. [Google Scholar] [CrossRef]
- Schieffer, G.; Peng, I. Accelerating Drug Discovery in AutoDock-GPU with Tensor Cores. In Proceedings of the 29th International Conference on Parallel and Distributed Computing, Limassol, Cyprus, 28 August–1 September 2023; pp. 608–622. [Google Scholar]
- Kalibaeva, G.; Ferrario, M.; Ciccotti, G. Constant Pressure-Constant Temperature Molecular Dynamics: A Correct Constrained NPT Ensemble Using the Molecular Virial. Mol. Phys. 2003, 101, 765–778. [Google Scholar] [CrossRef]
- David, C.C.; Jacobs, D.J. Principal Component Analysis: A Method for Determining the Essential Dynamics of Proteins. In Protein Dynamics: Methods and Protocols; Humana Press, Totowa, NJ, USA, 2014; pp. 193–226.
- Amadei, A.; Linssen, A.B.M.; Berendsen, H.J.C. Essential Dynamics of Proteins. Proteins Struct. Funct. Bioinform. 1993, 17, 412–425. [Google Scholar] [CrossRef] [PubMed]
- Deeks, E.D. Cobicistat: A Review of Its Use as a Pharmacokinetic Enhancer of Atazanavir and Darunavir in Patients with HIV-1 Infection. Drugs 2014, 74, 195–206. [Google Scholar] [CrossRef] [PubMed]
- Noble, S.; Faulds, D. Saquinavir: A Review of Its Pharmacology and Clinical Potential in the Management of HIV Infection. Drugs 1996, 52, 93–112. [Google Scholar] [CrossRef] [PubMed]
- Khan, M.L.; Stewart, A.K. Carfilzomib: A Novel Second-Generation Proteasome Inhibitor. Future Oncol. 2011, 7, 607–612. [Google Scholar] [CrossRef]
- Husain, A.; Azim, M.S.; Mitra, M.; Bhasin, P.S. A Review on Candesartan: Pharmacological and Pharmaceutical Profile. J. Appl. Pharm. Sci. 2011, 1, 12–17. [Google Scholar]
- Mangum, E.M.; Graham, K.K. Lopinavir-ritonavir: A New Protease Inhibitor. Pharmacother. J. Hum. Pharmacol. Drug Ther. 2001, 21, 1352–1363. [Google Scholar] [CrossRef]
- Plosker, G.L.; Noble, S. Indinavir: A Review of Its Use in the Management of HIV Infection. Drugs 1999, 58, 1165–1203. [Google Scholar] [CrossRef]
- Chung, K.F.; Barnes, P.J. Zafirlukast (Accolate). Drugs Today 1998, 34, 375–388. [Google Scholar] [CrossRef]
- Tiwari, S.R.; Mishra, P.; Abraham, J. Neratinib, a Novel HER2-Targeted Tyrosine Kinase Inhibitor. Clin. Breast Cancer 2016, 16, 344–348. [Google Scholar] [CrossRef] [PubMed]
- Morris, G.M.; Lim-Wilby, M. Molecular Docking. In Molecular Modeling of Proteins; Humana Press: Totowa, NJ, USA, 2008; pp. 365–382. [Google Scholar]
- Labello, N.P.; Bennett, E.M.; Ferguson, D.M.; Aldrich, C.C. Quantitative Three Dimensional Structure Linear Interaction Energy Model of 5′-O-[N-(Salicyl) Sulfamoyl] Adenosine and the Aryl Acid Adenylating Enzyme MbtA. J. Med. Chem. 2008, 51, 7154–7160. [Google Scholar] [CrossRef] [PubMed]
AutoDock 4.2.6 | |||||||
---|---|---|---|---|---|---|---|
Protein | Center Grid Box Dimensions (Å) | Spacing (Å) | Coordinates for the Center of the Grid Box | ||||
X-axis | Y-axis | Z-axis | 0.375 | X-axis | Y-axis | Z-axis | |
MbtA | 50 | 50 | 50 | −2.439 | 19.515 | 32.895 |
S. No. | Code | Structure | Compound Details | MOA and Therapeutic Application |
---|---|---|---|---|
1 | a_617 | ZINC ID: ZINC000085537014 Cobicistat Formula: C40H53N7O5S2 Molar mass: 776.03 g·mol−1 | Cobicistat (Tybost™) functions as a mechanism-based inhibitor of cytochrome P450 (CYP) 3A enzymes. It is approved in the EU as a pharmacokinetic enhancer, specifically a booster, of HIV-1 protease inhibitors (PIs) such as atazanavir and darunavir in adult patients [49] | |
2 | a_391 | ZINC ID: ZINC000003914596 Saquinavir Formula: C38H50N6O5 Molar mass: 670.855 g·mol−1 | Saquinavir was the first protease inhibitor developed for HIV therapy. It acts by cleaving viral polypeptide chains into functional proteins during the late stages of HIV replication [50] | |
3 | a_821 | ZINC ID: ZINC000049841054 Carfilzomib Formula: C38H50N6O5 Molar mass: 670.855 g·mol−1 | Carfilzomib (formerly PR-171) is a novel epoxyketone-based irreversible proteasome inhibitor. It specifically targets the chymotrypsin-like activity of the proteasome, preventing its normal function and causing a buildup of proteins within the cancer cells [51]. | |
4 | a_827 | ZINC ID: ZINC000004074875 Candesartan Formula: C24H20N6O3 Molar mass: 440.463 g·mol−1 | Candesartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively blocking the binding of angiotensin II to the AT1 receptor in many tissues, such as vascular smooth muscle and the adrenal gland [52]. | |
5 | a_85 | ZINC ID: ZINC000003944422 Ritonavir Formula: C37H48N6O5S2 Molar mass: 720.95 g·mol−1 | Ritonavir is a protease inhibitor and is used as a booster with other protease inhibitors in the treatment of HIV infection. It prevents the proper maturation of the virus [53]. | |
6 | a_472 | ZINC ID: ZINC000003951740 Lopinavir Formula: C37H48N4O5 Molar mass: 628.814 g·mol−1 | Lopinavir is an antiretroviral medication primarily used in the treatment of HIV infection. It acts as a protease inhibitor in the final stages of the viral replication process thereby preventing the proper maturation of the virus, leading to immature and non-functional viral particles [53]. | |
7 | a_1276 | ZINC ID: ZINC000022448696 Indinavir Formula: C36H47N5O4 Molar mass: 613.803 g·mol−1 | Indinavir is a protease inhibitor used as a component of highly active antiretroviral therapy to treat HIV/AIDS. It interferes with viral maturation, and contributes to the control of viral replication. It is also used as booster with other protease inhibitors [54]. | |
8 | a_1338 | ZINC ID: ZINC000150338755 Venetoclax Formula: C45H50ClN7O7S Molar mass: 867.320 g·mol−1 | Venetoclax is a B-cell lymphoma-2 (BCL-2) inhibitor. It binds to the BCL-2 protein, blocking its anti-apoptotic function | |
9 | a_797 | ZINC ID: ZINC000000896717 Accolate Formula: C31H33N3O6S Molar mass: 575.210 g·mol−1 | Zafirlukast (Accolate) is a leukotriene receptor antagonist. It inhibits the activity of leukotrienes by binding to their receptors found on various cells in the airways, causing bronchodilation [55]. | |
10 | a_1388 | ZINC ID: ZINC000003916214 Neratinib Formula: C30H29ClN6O3 Molar mass: 556.200 g·mol−1 | Neratinib is a tyrosine kinase inhibitor used in the treatment of certain types of breast cancers (targeted therapy). It works by irreversibly inhibiting multiple receptor tyrosine kinases, including HER2, epidermal growth factor receptor (EGFR), and HER4 [56]. |
S. No | Ligand | Runs | Binding Energy (kcal/mol) | ESTAT | HB | VDW | DSOLV |
---|---|---|---|---|---|---|---|
1 | a_617 | 200 | −16.69 | −0.9438 | −2.5163 | −23.9398 | 5.5597 |
2 | a_391 | 200 | −16.33 | −0.6982 | −2.18 | −21.8025 | 4.9488 |
3 | a_821 | 200 | −16.08 | −1.1546 | −1.562 | −23.9542 | 5.2432 |
4 | a_827 | 200 | −15.82 | −0.8058 | −1.9775 | −21.7725 | 4.9785 |
5 | a_85 | 200 | −14.84 | −0.3628 | −2.1603 | −20.6416 | 4.0052 |
6 | a_472 | 200 | −14.82 | −0.8465 | −2.6141 | −20.8497 | 5.0782 |
7 | a_1276 | 200 | −14.80 | −0.9278 | −2.6608 | −20.6792 | 5.1776 |
8 | a_1338 | 200 | −14.68 | −1.3963 | −1.6507 | −27.4664 | 6.791 |
9 | a_797 | 200 | −14.50 | −0.0758 | −1.9036 | −22.3757 | 4.7207 |
10 | a_1388 | 200 | −14.14 | −0.0544 | −1.7261 | −21.6482 | 4.6123 |
Sl. No. | Code | Docking Interactions with Active Site Amino Acid Residues | H-Bond Distance (Å) |
---|---|---|---|
1 | a_617 | H-bond-Asn258, Thr462, and Arg451 Hydrophobic-Val448, Asp436, Lys332, Phe353, Gly450, Gly330, Gly354, Leu360, Val352, Phe259, Cys263, Leu253, Ser213, Glu461, Ala356, Gly460, His257, Gly214, Met355, Thr216, Glu357, and Cys457 | 2.80, [3.06, 2.98], and [3.15, 2.48, 3.10] |
2 | a_391 | H-bond-Asn258, Thr462, Arg451, Gly460, Ala356, and Phe259 Hydrophobic-His257, Leu253, Glu461, Val302, Leu360, Val352, Gly354, Gly329, Gln376, Ser331, Gly330, Phe353, Lys332, Val448, Met355, Thr216, Glu357, Val212, Gly214, and Ser213 | 2.87, 2.81, [3.23, 3.21], 3.05, 2.92, and [2.87, 3.07] |
3 | a_821 | H-bond-Gly330, Thr462, and Arg451 Hydrophobic-Ala254, His257, Glu461, His523, Leu253, Leu126, His129, Gly214, Ser213, Val212, Met355, Ala356, Ser434, Glu357, Tyr432, Thr216, Val352, Lys332, Ser331, Phe353, Gly354, Gly460, and Ala459 | 2.95, 3.21, and 2.76 |
4 | a_827 | H-bond-Asn258, Arg451, Asp436, Gly354, and His257 Hydrophobic-Val212, Thr462, Glu461, Ala356, Val352, Gly330, Phe259, Leu360, Ser331, Phe353, Ser434, Tyr432, Met355, Tyr415, Gly214, Glu357, Thr216, and Ser213 | [2.82, 2.96], [3.16, 3.06], 2.72, 3.01, and 2.87 |
5 | a_85 | H-bond-Ala356, Val212, Gly354, and His257 Hydrophobic-Gly214, Val352, Gly330, Met355, Thr462, Phe259, Asn258, Pro260, Leu253, Phe353, Val302, Ser331, Gly460, Glu357, Leu126, Glu461, Arg451, Ser213, Val448, Cys457, and Asp436 | 2.88, 2.80, 2.96, and 3.08 |
6 | a_472 | H-bond-Gly354, Gly460, Thr462, and Arg451 Hydrophobic-Asp436, Val448, Phe353, Met355, Lys332, Gly330, Ser331, Val352, Phe259, Leu360, Gly214, Val212, His129, Ser213, Leu126, Ala356, Glu461, Ala459, His257, and Leu253 | 2.75, 2.92, 3.16, and 2.86 |
7 | a_1276 | H-bond-Gly354, and Arg451 Hydrophobic-Asp436, Phe353, Leu360, Phe259, Gly329, Val352, Asn258, Glu461, Val302, Gly330, His257, Ala254, Thr462, Leu253, Gly460, Ala356, Glu357, Tyr432, Thr216, Gly214, and Ser434 | 2.66 and [2.63, 2.93] |
8 | a_1338 | H-bond-Val352, Thr462, and Phe259 Hydrophobic-Gly460, Met355, Ser434, Tyr432, Arg451, Asp436, Cys457, Ile456, Gly450, Val455, Glu493, Glu334, Ser331, Val448, Lys332, Gly330, Phe353, Gly354, Gly329, Asn258, His257, Ala356, and Leu360 | 3.17, 2.83, and 3.15 |
9 | a_797 | H-bond-Asn258, His257, and Arg451 Hydrophobic-Glu461, Gly214, Gly460, Ser213, Thr462, Val212, Lys332, Asp436, Ser331, Cys457, Gly450, Val448, Phe353, Gly354, Val352, Gly330, Cys263, Leu360, Phe259, and Ala356 | 3.07, 3.04, and [2.87, 2.88] |
10 | a_1388 | H-bond-His257, Phe259, and Thr462 Hydrophobic-Arg451, Val352, Phe353, Gly329, Ser331, Val448, Gln376, Lys332, Gly330, Asp436, Met355, Gly354, Ser213, Gly214, Glu357, Ala356, Gly256, Pro260, Gly460, Val212, Glu461, Val302, Leu253, and Asn258 | 2.88, 2.94, and 2.94 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Rakshit, G.; Biswas, A.; Jayaprakash, V. In Silico Drug Repurposing Studies for the Discovery of Novel Salicyl-AMP Ligase (MbtA)Inhibitors. Pathogens 2023, 12, 1433. https://doi.org/10.3390/pathogens12121433
Rakshit G, Biswas A, Jayaprakash V. In Silico Drug Repurposing Studies for the Discovery of Novel Salicyl-AMP Ligase (MbtA)Inhibitors. Pathogens. 2023; 12(12):1433. https://doi.org/10.3390/pathogens12121433
Chicago/Turabian StyleRakshit, Gourav, Abanish Biswas, and Venkatesan Jayaprakash. 2023. "In Silico Drug Repurposing Studies for the Discovery of Novel Salicyl-AMP Ligase (MbtA)Inhibitors" Pathogens 12, no. 12: 1433. https://doi.org/10.3390/pathogens12121433